Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
XIAFLEX®
(collagenase clostridium histolyticum) Injection, for Intralesional Use
WARNING
CORPORAL RUPTURE (PENILE FRACTURE) OR OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE’S DISEASE
Corporal rupture (penile fracture) was reported as an adverse reaction in 5 of 1044 (0.5%) XIAFLEX-treated patients in clinical studies. In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile “popping” sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded. Severe penile hematoma was also reported as an adverse reaction in 39 of 1044 (3.7%) XIAFLEX-treated patients [see WARNINGS AND PRECAUTIONS].
Signs or symptoms that may reflect serious penile injury should be promptly evaluated to assess for corporal rupture or severe penile hematoma which may require surgical intervention [see WARNINGS AND PRECAUTIONS].
Because of the risks of corporal rupture or other serious penile injury, XIAFLEX is available for the treatment of Peyronie’s disease only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the XIAFLEX REMS Program [see WARNINGS AND PRECAUTIONS].
XIAFLEX contains purified collagenase clostridium histolyticum, consisting of two microbial collagenases in a defined mass ratio, Collagenase AUX-I and Collagenase AUX-II, which are isolated and purified from the fermentation of Clostridium histolyticum bacteria.
Collagenase AUX-I is a single polypeptide chain consisting of approximately 1000 amino acids of known sequence. It has an observed molecular weight of 114 kiloDaltons (kDa). It belongs to the class I Clostridium histolyticum collagenases.
Collagenase AUX-II is a single polypeptide chain consisting of approximately 1000 amino acids of deduced sequence. It has an observed molecular weight of 113 kDa. It belongs to the class II Clostridium histolyticum collagenases.
XIAFLEX is supplied as a sterile lyophilized powder (white cake) intended for reconstitution with the supplied sterile diluent (0.3 mg/mL calcium chloride dihydrate in 0.9% sodium chloride) prior to intralesional injection into a Dupuytren’s cord or a Peyronie’s plaque.
XIAFLEX is available in single-use, glass vials containing 0.9 mg of collagenase clostridium histolyticum. Each vial also contains 0.5 mg of hydrochloric acid, 18.5 mg of sucrose, and 1.1 mg of tromethamine.
XIAFLEX is indicated for the treatment of adult patients with Dupuytren's contracture with a palpable cord.
XIAFLEX is indicated for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.
XIAFLEX should be administered by a healthcare provider experienced in injection procedures of the hand and in the treatment of patients with Dupuytren's contracture.
XIAFLEX, supplied as a lyophilized powder, must be reconstituted with the provided diluent prior to use [see Dosage And Administration For Dupuytren's Contracture]. The dose of XIAFLEX is 0.58 mg per injection into a palpable cord with a contracture of a metacarpophalangeal (MP) joint or a proximal interphalangeal (PIP) joint [see Dosage And Administration For Dupuytren's Contracture]. Each vial of XIAFLEX and sterile diluent should only be used for a single injection. If two joints on the same hand are to be treated during a treatment visit, separate vials and syringes should be used for each reconstitution and injection.
Table 1 displays an overview of the volumes of sterile diluent for reconstitution and the reconstituted XIAFLEX solution to be used in the intralesional injection [see Dosage And Administration For Dupuytren's Contracture]. Approximately 24 to 72 hours after injection, perform a finger extension procedure if a contracture persists to facilitate cord disruption [see Dosage And Administration For Dupuytren's Contracture].
Table 1. Volumes Needed for Reconstitution and Administration for Dupuytren's Contracture
| For cords affecting MP joints | For cords affecting PIP joints | |
| Sterile Diluent for Reconstitution | ||
| Volume | 0.39 mL | 0.31 mL |
| Reconstituted XIAFLEX Solution to be Injected1 | ||
| Volume | 0.25 mL | 0.20 mL |
|
1 The reconstituted XIAFLEX solution to be used in the intralesional injection
contains 0.58 mg of XIAFLEX. Note: The entire reconstituted XIAFLEX solution contains 0.9 mg of XIAFLEX. Reconstituted XIAFLEX solution remaining in the vial after the injection should be discarded. |
||
Four weeks after the XIAFLEX injection and finger extension procedure, if a MP or PIP contracture remains, the cord may be re-injected with a single dose of 0.58 mg of XIAFLEX and the finger extension procedure may be repeated (approximately 24 to 72 hours after injection). Injections and finger extension procedures may be administered up to 3 times per cord at approximately 4-week intervals.
Perform up to two injections in the same hand according to the injection procedure during a treatment visit. Two palpable cords affecting two joints may be injected or one palpable cord affecting two joints in the same finger may be injected at two locations during a treatment visit. If patient has other palpable cords with contractures of MP or PIP joints, these cords may be injected with XIAFLEX at other treatment visits approximately 4 weeks apart.
XIAFLEX should be administered by a healthcare provider experienced in the treatment of male urological diseases, who has completed required training for use of XIAFLEX in the treatment of Peyronie's disease.
XIAFLEX, supplied as lyophilized powder, must be reconstituted with the provided diluent prior to use [see Dosage And Administration For Peyronie's Disease]. The dose of XIAFLEX is 0.58 mg per injection administered into a Peyronie's plaque. If more than one plaque is present, inject into the plaque causing the curvature deformity.
A treatment course consists of a maximum of 4 treatment cycles. Each treatment cycle consists of two XIAFLEX injection procedures [see Dosage And Administration For Peyronie's Disease] and one penile modeling procedure [see Dosage And Administration For Peyronie's Disease]. The second XIAFLEX injection procedure is performed 1 to 3 days after the first. The penile modeling procedure is performed 1 to 3 days after the second injection of the treatment cycle. The interval between treatment cycles is approximately six weeks. The treatment course therefore, consists of a maximum of 8 injection procedures and 4 modeling procedures.
If the curvature deformity is less than 15 degrees after the first, second or third treatment cycle, or if the healthcare provider determines that further treatment is not clinically indicated, then the subsequent treatment cycles should not be administered.
The safety of more than one treatment course of XIAFLEX is not known.
Table 2 displays an overview of the volume of sterile diluent for reconstitution and the reconstituted XIAFLEX solution to be used in the intralesional injection [see Dosage And Administration For Peyronie's Disease].
Table 2. Volumes Needed for Reconstitution and
Administration
| Sterile Diluent for Reconstitution | |
| Volume | 0.39 mL |
| Reconstituted XIAFLEX Solution to be Injected1 | |
| Volume | 0.25 mL |
|
1 The reconstituted XIAFLEX solution to be used in the intralesional
injection contains 0.58 mg of XIAFLEX. Note: The entire reconstituted XIAFLEX solution contains 0.9 mg of XIAFLEX. Reconstituted XIAFLEX solution remaining in the vial after the injection should be discarded. |
|
Penile modeling helps relieve curvature deformity and straighten the penile shaft. At a follow-up visit 1 to 3 days after the second injection of each treatment cycle, perform a penile modeling procedure (as described below) on the flaccid penis to stretch and elongate the treated plaque:
In addition to the in-office penile modeling procedure, patients should be instructed to self-perform penile modeling activities at home each day for the 6-week period following the investigator penile plaque modeling visit of each treatment cycle as follows:
XIAFLEX is supplied in single-use glass vials containing 0.9 mg of collagenase clostridium histolyticum as a sterile, lyophilized powder for reconstitution. Sterile diluent for reconstitution is provided in the package in a single-use glass vial containing 3 mL of 0.3 mg/mL calcium chloride dihydrate in 0.9% sodium chloride.
XIAFLEX is available in single-use, glass vials containing 0.9 mg of collagenase clostridium histolyticum as a sterile, lyophilized powder.
Sterile diluent for reconstitution is available in single-use, glass vials containing 3 mL of 0.3 mg/mL calcium chloride dihydrate in 0.9% sodium chloride.
| NDC Number | Package Size |
| 66887-003-01 | Single-use package: 1 carton containing a single-use vial of XIAFLEX and a single-use vial of sterile diluent |
| 66887-003-02 | Dual-Pack (two single-use packages): 1 box containing 2 cartons, each containing a single-use vial of XIAFLEX and a single-use vial of sterile diluent |
Prior to reconstitution, the vials of XIAFLEX and diluent should be stored in a refrigerator at 2° to 8°C (36° to 46°F) [see DOSAGE AND ADMINISTRATION]. Do not freeze.
The reconstituted XIAFLEX solution can be kept at room temperature (20° to 25°C/68° to 77°F) for up to one hour or refrigerated at 2° to 8˚C (36° to 46°F) for up to 4 hours prior to administration [see DOSAGE AND ADMINISTRATION].
Distributed by: Endo Pharmaceuticals Inc. Malvern, PA 19355. Revised: June 2018
The following serious adverse reactions in patients with Dupuytren’s contracture are discussed in greater detail elsewhere in the labeling:
The following serious adverse reactions in patients with Peyronie’s disease are discussed in greater detail elsewhere in the labeling:
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
Out of 1082 patients who received 0.58 mg of XIAFLEX in the controlled and uncontrolled portions of the XIAFLEX studies (2630 XIAFLEX injections), 3 (0.3%) patients had a flexor tendon rupture of the treated finger within 7 days of the injection.
The data described below are based on two pooled randomized, double-blind, placebo-controlled trials through Day 90 in patients with Dupuytren’s contracture (Studies 1 and 2). In these trials, patients were treated with up to 3 injections of 0.58 mg of XIAFLEX or placebo with approximately 4-week intervals between injections and the patients had finger extension procedures the day after injection, if needed, to facilitate disruption of the cord [see Clinical Studies]. These trials were comprised of 374 patients of whom 249 and 125 received 0.58 mg of XIAFLEX and placebo, respectively. The mean age was 63 years, 80% were male and 20% were female, and 100% were white.
In the placebo-controlled portions of Studies 1 and 2 through Day 90, 98% and 51% of XIAFLEX-treated and placebo-treated patients had an adverse reaction after up to 3 injections, respectively. Over 95% of XIAFLEX-treated patients had an adverse reaction of the injected extremity after up to 3 injections. Approximately 81% of these local reactions resolved without intervention within 4 weeks of XIAFLEX injections. The adverse reaction profile was similar for each injection, regardless of the number of injections administered. However, the incidence of pruritus increased with more injections [see WARNINGS AND PRECAUTIONS].
The most frequently reported adverse drug reactions (≥ 25%) in the XIAFLEX clinical trials in patients with Dupuytren’s contracture included edema peripheral (mostly swelling of the injected hand), contusion, injection site hemorrhage, injection site reaction, and pain in the treated extremity. Table 3 shows the incidence of adverse reactions that were reported in greater than or equal to 5% of XIAFLEX-treated patients and at a frequency greater than placebo-treated patients after up to 3 injections in the pooled placebo-controlled trials through Day 90 (Studies 1 and 2).
Table 3. Adverse Reactions Occurring in ≥ 5% of XIAFLEX-Treated
Patients with Dupuytren’s Contracture and at a Greater Incidence than
Placebo in the Placebo-Controlled Trials Through Day 90 After Up to 3
Injections
| Adverse Reaction | XIAFLEX N=249 |
Placebo N=125 |
| All Adverse Reactions | 98% | 51% |
| Edema Peripherala | 73% | 5% |
| Contusionb | 70% | 3% |
| Injection Site Hemorrhage | 38% | 3% |
| Injection Site Reactionc | 35% | 6% |
| Pain in Extremity | 35% | 4% |
| Tenderness | 24% | 0% |
| Injection Site Swellingd | 24% | 6% |
| Prurituse | 15% | 1% |
| Lymphadenopathyf | 13% | 0% |
| Skin Laceration | 9% | 0% |
| Lymph Node Pain | 8% | 0% |
| Erythema | 6% | 0% |
| Axillary Pain | 6% | 0% |
|
a Most of these events were swelling of the injected hand. b Includes the terms: contusion (any body system) and ecchymosis Includes the terms: injection site reaction, injection site erythema, injection site inflammation, injection site irritation, injection site pain, and injection site warmth c Includes the terms: injection site swelling and injection site edema d Includes the terms: pruritus and injection site pruritus e Includes the terms: lymphadenopathy and axillary mass |
||
Some patients developed vasovagal syncope after finger extension procedures.
The safety of two concurrent injections of XIAFLEX 0.58 mg into Dupuytren’s cords in the same hand was evaluated in a historically-controlled, open-label multi-center trial in 715 adult subjects with Dupuytren’s contracture (Study 3). In Study 3, finger extension procedures were performed approximately 24 to 72 hours after injection. The patient demographics were similar to Studies 1 and 2.
Out of 715 patients who received two concurrent injections of XIAFLEX 0.58 mg in the same hand (1450 XIAFLEX injections) in Study 3, one (0.1%) patient experienced a tendon rupture of the treated finger within 3 days of the injection.
Table 4 shows the incidence of adverse reactions that were reported in greater than or equal to 5% of XIAFLEX-treated patients after two concurrent injections of XIAFLEX in the same hand through Day 60 in Study 3.
Table 4. Adverse Reactions Occurring in ≥5.0% of
Subjects Who Received Two Concurrent Injections of
XIAFLEX in Study 3
| Adverse Reaction | XIAFLEX N=715 |
| Subjects with ≥1 adverse reaction | 95% |
| Edema peripheral | 77% |
| Contusion | 59% |
| Pain in extremity | 51% |
| Laceration | 22% |
| Pruritus | 15% |
| Injection site pain | 14% |
| Lymphadenopathy | 13% |
| Blood blister | 12% |
| Injection site hematoma | 8% |
| Axillary pain | 7% |
| Injection site hemorrhage | 6% |
| Injection site swelling | 5% |
| Ecchymosis | 5% |
An observational, open label study was conducted in subjects who had participated in XIAFLEX clinical trials for Dupuytren’s contracture (Study 4). A subset of patients who had recurrence of contracture in a joint that was previously successfully treated with XIAFLEX in Study 4 were retreated (Study 5). No new safety signals were identified among subjects who were retreated with XIAFLEX.
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
In the controlled and uncontrolled clinical studies of XIAFLEX in Peyronie’s disease, 1044 patients received a total of 7466 XIAFLEX injections.
The data described below are based on two identical, pooled, randomized, double-blind, placebo-controlled, multi-center trials through Day 365 in patients with Peyronie’s disease (Studies 1 and 2). These trials included 832 patients of whom 551 and 281 received XIAFLEX and placebo, respectively. In these trials, patients were given up to 4 treatment cycles of XIAFLEX or placebo. In each cycle, two injections of XIAFLEX or two injections of placebo were administered 1 to 3 days apart. A penile modeling procedure was performed at the study site on patients 1 to 3 days after the second injection of the cycle. The treatment cycle was repeated at approximately 6-week intervals up to three additional times, for a maximum of 8 total injection procedures and 4 total modeling procedures [see Clinical Studies].
The majority of Peyronie’s patients experienced at least one adverse reaction (92% XIAFLEX-treated patients, 61% placebo-treated). Most adverse reactions were local events of the penis and groin and the majority of these events were of mild or moderate severity, and most (79%) resolved within 14 days of the injection. The adverse reaction profile was similar after each injection, regardless of the number of injections administered.
The most frequently reported adverse drug reactions (≥ 25%) in the XIAFLEX clinical trials in patients with Peyronie’s disease were penile hematoma, penile swelling, and penile pain. Table 5 shows the incidence of adverse reactions that were reported in greater than or equal to 1% of XIAFLEX-treated patients and at a frequency greater than placebo-treated patients after up to 8 injections in the pooled placebo-controlled trials through Day 365.
Table 5. Adverse Reactions Occurring in ≥ 1% of XIAFLEX-Treated
Patients with Peyronie’s disease and at a Greater Incidence than Placebo
After Up to Four Treatment Cycles in Studies 1 and 2 Combined
| Adverse Reaction | XIAFLEX N=551 |
Placebo N=281 |
| All Adverse Reactions | 84.2% | 36.3% |
| Penile hematomaa | 65.5% | 19.2% |
| Penile swellingb | 55.0% | 3.2% |
| Penile painc | 45.4% | 9.3% |
| Penile ecchymosesd | 14.5% | 6.8% |
| Blood blister | 4.5% | 0 |
| Penile blister | 3.3% | 0 |
| Pruritus genital | 3.1% | 0 |
| Painful erection | 2.9% | 0 |
| Erectile dysfunction | 1.8% | 0.4% |
| Skin discoloration | 1.8% | 0 |
| Procedural pain | 1.6% | 0.7% |
| Injection site vesicles | 1.3% | 0 |
| Localized edema | 1.3% | 0 |
| Dyspareunia | 1.1% | 0 |
| Injection site pruritus | 1.1% | 0 |
| Nodule | 1.1% | 0 |
| Suprapubic pain | 1.1% | 0 |
|
a Includes: injection site hematoma and penile hematoma were reported with the verbatim
term of penile bruising or injection site bruising in 87% of subjects. b Includes: injection site swelling, penile edema, penile swelling, local swelling, scrotal swelling, and injection site edema. c Includes: injection site pain, penile pain, and injection site discomfort. d Includes: contusion, ecchymoses, penile hemorrhage, and injection site hemorrhage |
||
Severe penile hematoma or severe injection site hematoma were reported in 33/551 (6.0%) of XIAFLEX-treated patients and 0/281 (0%) of placebo-treated patients, in Studies 1 and 2 combined.
A popping noise or popping sensation in the penis, sometimes described as “snapping” or “cracking”, and sometimes accompanied by detumescence, hematoma and/or pain, were reported in 73/551 (13.2%) XIAFLEX-treated patients and 1/281 (0.3%) placebo-treated patients.
There were no clinically meaningful differences in the incidence of adverse events following treatment with XIAFLEX based on the severity of baseline erectile dysfunction or concomitant phosphodiesterase type 5 (PDE5) inhibitor use.
XIAFLEX was not associated with shortening of penile length in clinical trials in the treatment of Peyronie’s disease.
During clinical studies in Dupuytren’s contracture and Peyronie’s disease, patients were tested at multiple time points for antibodies to the protein components of XIAFLEX (AUX-I and AUXII).
In the Dupuytren’s contracture clinical studies (Studies 1 and 2), at 30 days post the first injection of XIAFLEX 0.58 mg, 92% of patients had antibodies against AUX-I detected and 86% of patients had antibodies against AUX-II detected. After the fourth injection of XIAFLEX, every XIAFLEX-treated patient developed high titers of antibodies to both AUX-I and AUX-II. After five years more than 90 percent of patients remained seropositive for anti-AUX-I and antiAUX- II antibody (Study 4). Neutralizing antibodies were assayed for all patients (204) in Study 1. Neutralizing antibodies to AUX-I or AUX-II, were detected in 10% and 21%, respectively, of patients treated with XIAFLEX. Among patients in Study 3 who reported no prior exposure to XIAFLEX, 97% of patients had antibodies against AUX-I and AUX-II after two concurrent doses of XIAFLEX 0.58 mg (total dose of 1.16 mg) in the same hand. In Study 5, treatment of recurrent contractures with XIAFLEX resulted in similar immunogenicity results as seen in Studies 1 and 2.
In the Peyronie’s disease clinical studies, at 6 weeks after the first treatment cycle of XIAFLEX 0.58 mg, approximately 75% of patients had antibodies against AUX-I and approximately 55% of patients had antibodies against AUX-II. Six weeks after the eighth injection (fourth treatment cycle) of XIAFLEX, >99% of XIAFLEX-treated patients developed high titers of antibodies to both AUX-I and AUX-II. Neutralizing antibodies were assayed for a subset of 70 samples selected to be representative of high and low titer binding antibody responses at week 12 of treatment. For each subject in whom a Week 12 sample was selected, the corresponding Week 6, 18, 24, and 52 samples were assayed if they were also binding antibody positive. Neutralizing antibodies to AUX-I or AUX-II, were detected in 60% and 51.8%, respectively, of patients tested.
In patients treated for these two indications, there was no apparent correlation of antibody frequency, antibody titers, or neutralizing status to clinical response or adverse reactions.
Since the protein components in XIAFLEX (AUX-I and AUX-II) have some sequence homology with human matrix metalloproteinases (MMPs), anti-product antibodies could theoretically interfere with human MMPs. In vitro studies showed no evidence of cross-reactivity between anti-drug-antibody positive patient sera and a series of relevant MMPs. In addition, no clinical safety concerns related to the inhibition of endogenous MMPs have been observed.
Immunogenicity assay results are highly dependent on the sensitivity and specificity of the assay used in detection and may be influenced by several factors, including sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of incidence of antibodies to collagenase clostridium histolyticum with the incidence of antibodies to other products may be misleading.
Anticoagulant drugs: XIAFLEX should be used with caution in patients receiving concomitant anticoagulants (except for low-dose aspirin) [see WARNINGS AND PRECAUTIONS].
Included as part of the "PRECAUTIONS" Section
In the controlled and uncontrolled portions of clinical trials in Dupuytren’s contracture, flexor tendon ruptures occurred after XIAFLEX injection [see ADVERSE REACTIONS]. Injection of XIAFLEX into collagen-containing structures such as tendons or ligaments of the hand may result in damage to those structures and possible permanent injury such as tendon rupture or ligament damage. Therefore, XIAFLEX should be injected only into the collagen cord with a MP or PIP joint contracture, and care should be taken to avoid injecting into tendons, nerves, blood vessels, or other collagen-containing structures of the hand. When injecting a cord affecting a PIP joint of the fifth finger, the needle insertion should not be more than 2 to 3 mm in depth and avoid injecting more than 4 mm distal to the palmar digital crease [see DOSAGE AND ADMINISTRATION].
Other XIAFLEX-associated serious local adverse reactions included pulley rupture, ligament injury, complex regional pain syndrome (CRPS), sensory abnormality of the hand, and skin laceration (tear). In a historically controlled post-marketing trial, the incidence of skin laceration (22%) was higher for subjects treated with two concurrent injections of XIAFLEX compared with subjects treated with up to three single injections in the placebo-controlled premarketing trials (9%). Cases of skin laceration requiring skin graft after finger extension procedures have been reported post-marketing. Signs or symptoms that may reflect serious injury to the injected finger/hand should be promptly evaluated because surgical intervention may be required.
Corporal rupture was reported as an adverse reaction after XIAFLEX injections in 5 of 1044 (0.5%) XIAFLEX treated patients in the controlled and uncontrolled clinical trials in Peyronie’s disease.
In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile “popping” sound or sensation was reported, and in these cases, a diagnosis of corporal rupture can not be excluded. These patients were managed without surgical intervention, but the long-term consequences are unknown.
Severe penile hematoma was also reported as an adverse reaction in 39 of 1044 patients (3.7%) in the controlled and uncontrolled clinical trials in Peyronie’s disease [see ADVERSE REACTIONS].
Signs or symptoms that may reflect serious injury to the penis should be promptly evaluated in order to assess for corporal rupture or severe penile hematoma, which may require surgical intervention.
Injection of XIAFLEX into collagen-containing structures such as the corpora cavernosa of the penis may result in damage to those structures and possible injury such as corporal rupture (penile fracture). Therefore, XIAFLEX should be injected only into the Peyronie’s plaque and care should be taken to avoid injecting into the urethra, nerves, blood vessels, corpora cavernosa or other collagen-containing structures of the penis.
Because of the risks of corporal rupture (penile fracture) or other serious penile injury in the treatment of Peyronie’s disease, XIAFLEX is available only through the XIAFLEX REMS Program [see Corporal Rupture (Penile Fracture) Or Other Serious Injury To The Penis In The Treatment Of Peyronie’s Disease].
Required components of the XIAFLEX REMS Program include the following:
Further information is available at www.XIAFLEXREMS.com or 1-877-313-1235.
In the controlled portions of the clinical trials in Dupuytren’s contracture (Studies 1 and 2), a greater proportion of XIAFLEX-treated patients (15%) compared to placebo-treated patients (1%) had mild allergic reactions (pruritus) after up to 3 injections. The incidence of XIAFLEX-associated pruritus increased after more XIAFLEX injections in patients with Dupuytren’s contracture.
In the double-blind, placebo-controlled portions of the clinical trials in Peyronie’s disease (Studies 1 and 2), a greater proportion of XIAFLEX-treated patients (4%) compared to placebo-treated patients (1%) had localized pruritus after up to 4 treatment cycles (involving up to 8 XIAFLEX injection procedures). The incidence of XIAFLEX-associated pruritus was similar after each injection regardless of the number of injections administered.
Because XIAFLEX contains foreign proteins, severe allergic reactions to XIAFLEX can occur. Anaphylaxis was reported in a post-marketing clinical trial (Study 3) in one patient who had previous exposure to XIAFLEX for the treatment of Dupuytren’s contracture. Some patients with Dupuytren’s contracture developed IgE-anti-drug antibodies in greater proportions and higher titers with successive XIAFLEX injections. Healthcare providers should be prepared to address severe allergic reactions following XIAFLEX injections.
In the XIAFLEX trials in Dupuytren’s contracture (Studies 1 and 2), 70% and 38% of XIAFLEX-treated patients developed an ecchymosis/contusion or an injection site hemorrhage, respectively (see Table 3). In the XIAFLEX controlled trials in Peyronie’s disease (Studies 1 and 2), 65.5% of XIAFLEX-treated patients developed penile hematoma, and 14.5% developed penile ecchymosis (see Table 4). Patients with abnormal coagulation (except for patients taking low-dose aspirin, e.g., up to 150 mg per day) were excluded from participating in these studies.
Therefore, the efficacy and safety of XIAFLEX in patients receiving anticoagulant medications (other than low-dose aspirin, e.g., up to 150 mg per day) within 7 days prior to XIAFLEX administration is not known. In addition, it is recommended to avoid use of XIAFLEX in patients with coagulation disorders, including patients receiving concomitant anticoagulants (except for low-dose aspirin).
See FDA-approved patient labeling (PATIENT INFORMATION).
Advise patients of the following:
After the XIAFLEX injections, instruct patients:
Following the finger extension procedure(s) and fitting patient with a splint, instruct patients:
Advise patients of the following:
After the XIAFLEX injections, instruct the patient:
Provide the patient instructions on the appropriate technique to perform penile modeling activities at home, as described in “What You Need to Know About XIAFLEX Treatment for Peyronie's Disease: A Patient Guide”, and give the patient a copy.
Long-term animal studies to evaluate the carcinogenic potential of collagenase clostridium histolyticum have not been conducted.
Purified collagenase clostridium histolyticum was not mutagenic in Salmonella typhimurium (AMES test) and was not clastogenic in both an in vivo mouse micronucleus assay and an in vitro chromosomal aberration assay in human lymphocytes.
Collagenase clostridium histolyticum did not impair fertility and early embryonic development when administered intravenously in rats at exposures up to approximately 11 times the maximum recommended human dose (MRHD) on a mg/m2 basis.
There are no adequate and well-controlled studies of XIAFLEX in pregnant women.
Because animal reproduction studies are not always predictive of human response, XIAFLEX should be used during pregnancy only if clearly needed.
Risk Summary
Based on animal data, XIAFLEX is not predicted to increase the risk for major developmental abnormalities in humans.
Human Data
Human pharmacokinetic studies showed that XIAFLEX levels were not quantifiable in the systemic circulation following injection into a Dupuytren’s cord.
Low levels of XIAFLEX were quantifiable in the plasma of evaluable male subjects for up to 30 minutes following administration of XIAFLEX into the penile plaque of subjects with Peyronie’s disease [see CLINICAL PHARMACOLOGY].
Almost all patients develop anti-product antibodies (anti-AUX-I and anti-AUX-II) after treatment with XIAFLEX, and the clinical significance of anti-product antibody formation on a developing fetus is not known [see ADVERSE REACTIONS].
Animal Data
Reproduction studies have been performed in rats with intravenous exposures up to approximately 11 times the maximum recommended human dose (MRHD) of XIAFLEX on a mg/m2 basis, and have revealed no evidence of impaired fertility or harm to the fetus due to collagenase clostridium histolyticum.
It is not known whether collagenase clostridium histolyticum is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when XIAFLEX is administered to a nursing woman.
The safety and effectiveness of XIAFLEX in pediatric patients less than 18 years old have not been established.
Of the 249 XIAFLEX-treated patients in the double-blind, placebo-controlled, clinical trials in Dupuytren’s contracture (Studies 1 and 2), 104 (42%) were 65 years of age or older and 9% were 75 years of age or older. Of the 551 XIAFLEX-treated patients in the double-blind, placebo-controlled, clinical trials in Peyronie’s disease (Studies 1 and 2), 100 (18%) were 65 years of age or older and 5 (0.9 %) were 75 years of age or older. No overall differences in safety or effectiveness of XIAFLEX were observed between these patients and younger patients.
The effects of overdose of XIAFLEX are unknown. It is possible that multiple simultaneous or excessive doses of XIAFLEX may cause more severe local effects than the recommended doses including serious adverse reactions in the injected area (e.g., tendon ruptures or corporal ruptures dependent on the injection site). Supportive care and symptomatic treatment are recommended in these circumstances.
XIAFLEX is contraindicated in:
Collagenases are proteinases that hydrolyze collagen in its native triple helical conformation under physiological conditions, resulting in lysis of collagen deposits.
Injection of XIAFLEX into a Dupuytren’s cord, which is comprised mostly of collagen, may result in enzymatic disruption of the cord.
The signs and symptoms of Peyronie’s disease are caused by a collagen plaque. Injection of XIAFLEX into a Peyronie’s plaque, which is comprised mostly of collagen, may result in enzymatic disruption of the plaque. Following this disruption of the plaque, penile curvature deformity and patient bother caused by Peyronie’s disease are reduced [see Clinical Studies].
Results of in vitro studies, including those of explant tissues containing Peyronie’s plaques, suggest that XIAFLEX disrupts the predominant collagen found in plaques (Types I and III). At higher doses and longer incubation times, non-fibrillar Type IV collagen was affected causing collagen lysis in small veins, but did not cause structural damage to arteries, nerves or large veins which contain Type IV collagen in in vitro or in vivo studies.
Results of in vitro studies suggest that the collagenases (AUX-I and AUX-II) worked synergistically to provide hydrolyzing activity towards collagen. However, there are no clinical data regarding the relative contributions of the individual collagenases (AUX-I or AUX-II) to the efficacy of XIAFLEX in the treatment of Dupuytren’s contracture or Peyronie’s disease.
Collagen fragments generated from clostridial collagenase have been shown to generate increased vascular permeability, inflammatory responses, and regenerative changes. However, the effects of the formation of the collagen fragments derived from the collagen plaque are unknown.
Following administration of either a single injection of XIAFLEX 0.58 mg into a Dupuytren’s cord in 20 patients or two concurrent injections of XIAFLEX 0.58 mg into Dupuytren’s cords of 12 patients, no quantifiable levels of XIAFLEX (AUX-I or AUX-II) were detected in plasma up to 30 days post injection.
Following each of two intralesional administrations, separated by 24 hours, of XIAFLEX 0.58 mg into the penile plaque of 19 subjects with Peyronie’s disease, plasma levels of AUX-I and AUX-II in subjects with quantifiable levels (79% and 40% for AUX-I and AUX-II, respectively) were minimal and short-lived. The maximal plasma concentrations of AUX-I and AUX-II were <29 ng/mL and <71 ng/mL, respectively, and were observed approximately within 10 minutes after injection. All plasma levels were below the limits of quantification within 30 minutes following dosing. There was no evidence of accumulation following two sequential injections of XIAFLEX administered 24 hours apart. No subject had quantifiable plasma levels 15 minutes after modeling of plaque on Day 3 (i.e., 24 hours after Injection 2 on Day 2).
Single or repeat-dose intravenous studies of collagenase clostridium histolyticum in rats were conducted to evaluate the toxicological impact of injection of collagenase clostridium histolyticum directly into the systemic circulation. Dose-dependent liver toxicity was noted at exposures greater than or equal to approximately 11 times the MRHD on a mg/m2 basis as characterized by elevated aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels, increased liver weights, mild regenerative anemia with secondary changes in the spleen and histologic findings of chronic active inflammation, hemorrhage/hematoma, fibrosis, bile duct hyperplasia and/or hepatocellular necrosis. The histologic findings remained unresolved following a 2-week recovery period, while the other findings resolved completely. Animals that were found dead or prematurely euthanized had histopathological findings of hemorrhage and necrosis in the liver and extramedullary hematopoiesis in the liver and/or spleen. Death occurred at approximately 25 times the MRHD on a mg/m2 basis between study days 7 and 15 following 8 repeat intravenous administrations of collagenase clostridium histolyticum over 16 days or after single intravenous doses at approximately 40 times the MRHD on a mg/m2 basis.
In intermittent 13-week subcutaneous repeat-dose studies in rats or dogs administered doses up to approximately 3 times the MRHD on a mg/m2 basis, respectively, there was no evidence of systemic toxicity. In a single-dose phase or 61-day repeat-dose phase (3 times a week every 3 weeks for 3 cycles) study of intrapenile administration of collagenase clostridium histolyticum in dogs at exposures lower than or equal to the MRHD on a mg/m2 basis, there was no evidence of systemic toxicity.
The efficacy of 0.58 mg of XIAFLEX was evaluated in two randomized, double-blind, placebo-controlled, multi-centered trials in 374 adult patients with Dupuytren’s contracture (Studies 1 and 2). At study entry, patients must have had: (1) a finger flexion contracture with a palpable cord of at least one finger (other than the thumb) of 20 ° to 100 ° in a metacarpophalangeal (MP) joint or 20 ° to 80 ° in a proximal interphalangeal (PIP) joint and (2) a positive “table top test” defined as the inability to simultaneously place the affected finger(s) and palm flat against a table top. Patients could not have received a surgical treatment (e.g., fasciectomy, fasciotomy) on the selected primary joint within 90 days before the first injection of study medication and patients could not have received anticoagulation medication (except for up to 150 mg of aspirin per day) within 7 days before the first injection of study medication.
The cord affecting the selected primary joint received up to 3 injections of 0.58 mg of XIAFLEX or placebo on Days 0, 30, and 60. About 24 hours after each injection of study medication, if needed, the investigator manipulated (extended) the treated finger in an attempt to facilitate rupture of the cord (finger extension procedure). Following manipulation, patients were fitted with a splint, instructed to wear the splint at bedtime for up to 4 months, and instructed to perform a series of finger flexion and extension exercises each day.
Table 6 shows the baseline disease characteristics of patients with Dupuytren’s contracture in Studies 1 and 2.
Table 6. Baseline Disease Characteristics of Patients with Dupuytren’s Contracture
| Study 1 | Study 2 | |
| Proportion of patients with prior surgery for Dupuytren’s contracture1 | 38% | 53% |
| Proportion of patients with prior surgery for Dupuytren’s contracture on the same finger as the primary joint1 | 8% | 18% |
| Mean number of affected joints | 3.0 | 3.3 |
| 1 Prior surgery for Dupuytren’s contracture included fasciotomy and fasciectomy | ||
In Studies 1 and 2, the primary endpoint was to evaluate the proportion of patients who achieved a reduction in contracture of the selected primary joint (MP or PIP) to within 0° to 5° of normal, 30 days after the last injection of that joint on Days 30, 60, or 90 (after up to 3 injections). As shown in Table 7, a greater proportion of XIAFLEX-treated patients compared to placebo-treated patients achieved the primary endpoint.
Table 7. Percentage of Patients Who Achieved Reduction in Contracture of the Primary Joint to 0° to 5° After Up to 3 Injections in Studies 1 and 2a
| Treated Joint | Study 1 | Study 2 | ||
| XIAFLEXb | Placebo | XIAFLEXb | Placebo | |
| All Joints (MP and PIP)c,d Difference (CIe) |
N=203 | N=103 | N=45 | N=21 |
| 64% 57% (47%, 67%) |
7% - | 44% 40% (14%, 62%) |
5% - | |
MP Jointsc |
N=133 | N=69 | N=20 | N=11 |
| 77% 69% (57%, 79%) |
7% - | 65% 56% (19%, 83%) |
9% - | |
| PIP Jointsd Difference (CIe) |
N=70 | N=34 | N=25 | N=10 |
| 40% 34% (14%, 52%) |
6% - | 28% 28% (-10%, 61%) |
0% - | |
|
a Patients may have received up to 3 injections of study medication into the cords associated with contracture of the primary joints on Days 0, 30, and 60. Assessments were made 30 days after the last injection (on Days 30, 60, or 90). b For XIAFLEX-treated patients, the mean (±SD) number of injections given to the cord associated with the contracture was 1.7 (±0.8) in the 90-day controlled period in each trial. c MP joints are metacarpophalangeal joints d PIP joints are proximal interphalangeal joints e 95% confidence interval |
||||
The proportion of patients who achieved a contracture reduction of the primary joint to 0° to 5° after the first injection was 39% and 1% in Study 1 and 27% and 5% in Study 2 in the XIAFLEX and placebo groups respectively.
XIAFLEX-treated patients, compared to placebo-treated patients, showed a greater increase from baseline in the range of motion of MP and PIP joints (see Table 8).
Table 8. Mean Increase in Range of Motion from Baseline in Degrees
After Up to 3 Injections in Studies 1 and 2a
| Treated Joint | Study 1 | Study 2 | ||
| XIAFLEX | Placebo | XIAFLEX | placebo | |
| All Joints b,c | N=196 | N=102 | N=45 | N=21 |
| Baseline | 44 (20) | 45 (19) | 40 (15) | 44 (16) |
| Final | 80 (20) | 50 (22) | 76 (18) | 52 (20) |
| Increase | 36 (21) | 4 (15) | 35 (18) | 8 (15) |
| MP Joints b | N=129 | N=68 | N=20 | N=11 |
| Baseline | 43 (20) | 46 (19) | 40 (12) | 41 (21) |
| Final | 83 (16) | 50 (21) | 80 (11) | 50 (22) |
| Increase | 41 (20) | 4 (13) | 40 (13) | 9 (15) |
| PIP Joints c | N=67 | N=34 | N=25 | N=10 |
| Baseline | 46 (20) | 44 (18) | 41 (18) | 47 (10) |
| Final | 75 (24) | 49 (24) | 73 (21) | 54 (18) |
| Increase | 28 (22) | 5 (19) | 32 (20) | 7 (16) |
|
a Patients may have received up to 3 injections of study medication into the cords associated with contracture of
the primary joints on Days 0, 30, and 60. Assessments were made 30 days after the last injection (on Days 30,
60, or 90). Baseline and final range of motion degree values are expressed in mean (SD). a MP = Metacarpophalangeal joint c PIP = Proximal interphalangeal joint Range of Motion = Degrees of Full Flexion minus Degrees of Fixed Extension Not all patients had range of motion values at both time points. |
||||
A long term, observational, Year 2 to Year 5 follow-up study (Study 4) was undertaken to evaluate recurrence of contracture and long-term safety in subjects who received up to 8 single injections of XIAFLEX 0.58mg in a previous Phase 3 open-label or double-blind with open-label extension study. Of the 950 patients eligible for Study 4, only 645 patients enrolled. Of the 645 patients enrolled, 30% discontinued the study. Recurrence was assessed in successfully treated joints (i.e., subjects had a reduction in contracture to 5° or less at the Day 30 evaluation after the last injection of XIAFLEX in a previous study) and was defined as an increase in joint contracture by at least 20° in the presence of a palpable cord, or the joint underwent medical or surgical intervention primarily to correct a new or worsening Dupuytren’s contracture in that joint. Data on remaining recurrence free following successful treatment with XIAFLEX are provided in Figure 1.
Figure 1. Kaplan-Meier Plot Displaying Estimated Probability of Remaining Recurrence-Free over Time in the Observational Study 4 among Joints that were Successfully Treated in a Previous Study
 |
Study 5 retreated a subset of patients from Study 4 for a joint that was previously successfully treated but had recurrence. Patients in Study 5 received up to 3 injections of XIAFLEX (0.58 mg). Of the 91patients eligible for Study 5, 52 patients enrolled. In Study 5, 65% of recurrent MP joints and 45% of recurrent PIP joints achieved clinical success after retreatment with up to three injections of XIAFLEX. There was no control group for comparison in Study 5.
The efficacy of XIAFLEX was evaluated in two randomized, double-blind, placebo-controlled, multi-centered trials in 832 adult males with Peyronie’s disease (Studies 1 and 2). At study entry, patients must have had penile curvature deformity of at least 30 degrees in the stable phase of Peyronie’s disease. Patients were excluded if they had a ventral curvature deformity, an isolated hourglass deformity or a calcified plaque that could have interfered with the injection technique. At baseline, penile pain was either not present or was mild in most (98%) patients.
In these trials, patients were given up to 4 treatment cycles of XIAFLEX or placebo (weeks 0, 6, 12, 18), and were followed in a non-treatment follow-up period (weeks 24 -52). In each treatment cycle, two injections of XIAFLEX or two injections of placebo were administered 1 to 3 days apart. A penile modeling procedure was performed on patients at the study site 1 to 3 days after the second injection of the cycle. The treatment cycle was repeated at approximately six-week intervals for up to three additional times, for a maximum of 8 total injection procedures and 4 total modeling procedures. In addition, patients were instructed to perform penile modeling at home for six weeks after each treatment cycle [see PATIENT INFORMATION].
Table 9 shows the baseline disease characteristics of patients with Peyronie’s disease in Studies 1 and 2.
Table 9. Baseline Disease Characteristics of Patientsa with Peyronie’s Disease (PD)
| study 1 | study 2 | |||
| XIAFLEX N=277 |
Placebo N=140 |
XIAFLEX N=274 |
Placebo N=141 |
|
| Mean age (years) (Min-Max |
57.9 (28 -79) |
58.2 (30 -81) |
57.3 (23 -84) |
57.6 (33 -78) |
| Mean duration of PD (years) (Min-Max) |
3.9 (1.0 -35.9) |
4.8 (1.0 -50.8) |
4.2 (1.1 -30.9) |
3.4 (1.1 -47.1) |
| Mean Penile Curvature Deformity (degrees) (Min-Max) |
48.8 (30-90) |
49.0 (30-89) |
51.3 (30-90) |
49.6 (30-85) |
| Peyronie’s Disease Questionnaire (PDQ)b, – Mean Patient-Reported PD Bother Domain Score (range: 0-16) c | 7.5 | 7.4 | 7.4 | 8.4 |
| History of Erectile Dysfunction N (%) | 128 (46.2) | 75 (53.6) | 134 (48.9) | 76 (53.9) |
|
a Subjects were from ITT population and received at least one dose of study drug in Study 1 or 2 b Each PDQ assessment required subjects to have had vaginal intercourse in the 3 months prior to completion c Higher scores represent worse symptoms |
||||
Before the first dose of study drug was administered, eligible subjects were stratified by the degree of curvature deformity (30 to 60 degrees, and 61 to 90 degrees) and then randomized into two treatment groups to receive either XIAFLEX or placebo in a 2:1 ratio. The efficacy population (modified intent-to-treat (mITT) population) comprised a total of 612 intent-to-treat subjects who had both a curvature deformity measurement and a PDQ assessment at baseline, and at one or more subsequent time points in Studies 1 and 2, and had engaged in vaginal intercourse within 3 months prior to each PDQ assessment.
In Studies 1 and 2, the co-primary endpoints were:
The Bother domain score is a composite of the following patient-reported items: concern about erection pain, erection appearance, and the impact of Peyronie’s disease on intercourse and on frequency of intercourse.
XIAFLEX treatment significantly improved penile curvature deformity in patients with Peyronie’s disease compared with placebo (see Table 10). The improvement in curvature deformity was numerically similar among subjects with baseline curvature deformity from 30 to 60 degrees and those with curvature deformity from 61 to 90 degrees.
Table 10. Mean Percent Change in Penile Curvature Deformity from Baseline to Week 52 – Studies 1 and 2
| Study 1 | Study 2 | |||
| XIAFLEX N=199 |
Placebo N=104 |
XIAFLEX N=202 |
Placebo N=107 |
|
| Baseline Mean (degrees) | 48.8° | 49.0° | 51.3° | 49.6° |
| Mean Percent Change a | -35.0% | -17.8% | -33.2% | -21.8% |
| Treatment Difference (95% CI) |
-17.2% b (-26.7%, -7.6%) |
-11.4% b (-19.5%, -3.3%) |
||
|
a Mean percent change, treatment difference, 95% CI, and p-value were based on an ANOVA model with factors for treatment, stratum of baseline penile curvature, and their interaction and using last observation carried forward (LOCF) in the modified intent-to-treat (mITT) population. The mITT population was defined as all randomized subjects who had both a penile curvature deformity measurement and a PDQ assessment at baseline and at one or more subsequent time points. b p-value < 0.01 |
||||
Figure 2. Mean Percent Change in Penile Curvature Deformity –Study 1
 |
ANOVA model -adjusted values with factors for treatment, stratum of baseline penile curvature, and their interaction and using last observation carried forward (LOCF) in the modified intent-to-treat (mITT) population.
Figure 3. Mean Percent Change in Penile Curvature Deformity – Study 2
 |
ANOVA model -adjusted values with factors for treatment, stratum of baseline penile curvature, and their interaction and using last observation carried forward (LOCF) in the modified intent-to-treat (mITT) population.
XIAFLEX significantly reduced patient-reported bother associated with Peyronie’s disease compared with placebo (see Table 11). The reduction in the bother domain score was numerically similar between patient groups stratified by degree of baseline curvature deformity (30 to 60 degrees, and 61 to 90 degrees).
Table 11. Mean Change in Peyronie’s Disease Bother Domain Score from Baseline to Week 52 -Studies 1 and 2
| Study 1 | Study 2 | |||
| XIAFLEX N=199 |
Placebo N=104 |
XIAFLEX N=202 |
Placebo N=107 |
|
| Baseline Mean | 7.5 | 7.4 | 7.4 | 8.2 |
| Mean Changea | -2.8 | -1.6 | -2.6 | -1.5 |
| Treatment Difference (95% CI) |
-1.2 b (-2.4, -0.03) |
-1.1 b (-2.1, -0.002) |
||
|
a Mean change, treatment difference, 95% CI, and p-value all based on an ANOVA model with factors for treatment, stratum of baseline penile curvature, and their interaction and using last observation carried forward (LOCF) in the modified intent-to-treat (mITT) population. The mITT population was defined as all randomized subjects who had both a penile curvature deformity measurement and a PDQ assessment at baseline and at one or more subsequent time points. b p-value < 0.05. |
||||
Figure 4. Mean Change in Patient-Reported Peyronie’s Disease Bother Domain
Score – Study 1
 |
ANOVA model -adjusted values with factors for treatment, stratum of baseline penile curvature, and their interaction and using last observation carried forward (LOCF) in the modified intent-to-treat (mITT) population.
Figure 5. Mean Change in Patient-Reported Peyronie’s Disease Bother Domain Score
– Study 2
 |
ANOVA model –adjusted values with factors for treatment, stratum of baseline penile curvature, and their interaction and using last observation carried forward (LOCF) in the modified intent-to-treat (mITT) population.
There were no clinically meaningful differences in the mean percent improvement in curvature deformity or mean reduction in the bother domain score following treatment with XIAFLEX based on the severity of baseline erectile dysfunction or concomitant phosphodiesterase type 5 (PDE5) inhibitor use.
XIAFLEX®
(Zï a flex)
(collagenase clostridium histolyticum)
for injection, for intralesional use
XIAFLEX is approved for two uses: Dupuytren's contracture and Peyronie's disease. Information is provided separately for each use. Use for treating Dupuytren's contracture is described first, followed by use for treating Peyronie's disease.
Read this Medication Guide before you receive XIAFLEX for the treatment of Dupuytren’s contracture and each time you get an injection. There may be new information. This Medication Guide does not take the place of talking with your healthcare provider about your medical condition or treatment.
What is the most important information I should know about XIAFLEX for the treatment of Dupuytren’s contracture?
XIAFLEX can cause serious side effects, including:
Call your healthcare provider right away if you have any of these symptoms of an allergic reaction after an injection of XIAFLEX:
What is XIAFLEX?
XIAFLEX is a prescription medicine used to treat adults with Dupuytren’s contracture when a “cord” can be felt.
It is not known if XIAFLEX is safe and effective in children under the age of 18.
Who should not receive XIAFLEX?
Do not receive XIAFLEX if you:
Talk to your healthcare provider before receiving this medicine if you have any of these conditions.
What should I tell my healthcare provider before receiving XIAFLEX?
Before receiving XIAFLEX, tell your healthcare provider if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Using XIAFLEX with certain other medicines can cause serious side effects.
Especially tell your healthcare provider if you take:
Ask your healthcare provider or pharmacist for a list of these medicines, if you are not sure.
Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.
How will I receive XIAFLEX?
What are the possible side effects of XIAFLEX?
XIAFLEX may cause serious side effects, including:
The most common side effects with XIAFLEX for the treatment of Dupuytren’s contracture include:
Tell your healthcare provider if you have any side effect that bothers you or does not go away.
These are not all of the possible side effects with XIAFLEX. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
General information about the safe and effective use of XIAFLEX.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide.
This Medication Guide summarizes the most important information about XIAFLEX. If you would like more information, talk to your healthcare provider. You can ask your healthcare provider or pharmacist for information about XIAFLEX that is written for health professionals.
For more information, go to www.XIAFLEX.com or call 1-800-462-3636.
What are the ingredients in XIAFLEX?
Active ingredient: collagenase clostridium histolyticum
Inactive ingredients: hydrochloric acid, sucrose, and tromethamine. The diluent contains: calcium chloride dihydrate in 0.9% sodium chloride
XIAFLEX®
(Zï a flex)
(collagenase clostridium histolyticum)
for injection, for intralesional use
XIAFLEX is approved for two uses: Dupuytren's contracture and Peyronie's disease. Information is provided separately for each use. Use for treating Dupuytren's contracture is described on the previous pages, and use for treating Peyronie's disease is described below.
Read this Medication Guide before you receive XIAFLEX for the treatment of Peyronie’s disease and each time you get an injection. There may be new information. This Medication Guide does not take the place of talking with your healthcare provider about your medical condition or treatment.
Your healthcare provider will also talk to you about receiving XIAFLEX for the treatment of Peyronie’s disease using the “What You Need to Know About XIAFLEX Treatment for Peyronie’s Disease: A Patient Guide”. You can ask your healthcare provider for a copy of the Patient Guide.
What is the most important information I should know about XIAFLEX for the treatment of Peyronie’s disease?
XIAFLEX can cause serious side effects, including:
Symptoms of corporal rupture or other serious injury to your penis may include:
Call your healthcare provider right away if you have any of the symptoms of corporal rupture or serious injury to the penis listed above.
Do not have sex or any other sexual activity between the first and second injections of a treatment cycle.
Do not have sex or have any other sexual activity for at least 4 weeks after the second injection of a treatment cycle with XIAFLEX and after any pain and swelling has gone away.
XIAFLEX for the treatment of Peyronie’s disease is only available through a restricted program called the XIAFLEX Risk Evaluation and Mitigation Strategy (REMS) Program. For more information about the XIAFLEX REMS Program go to www.XIAFLEXREMS.com or call 1-877-942-3539.
Call your healthcare provider right away if you have any of these symptoms of an allergic reaction after an injection of XIAFLEX:
What is XIAFLEX?
XIAFLEX is a prescription medicine used to treat adult men with Peyronie’s disease who have a “plaque” that can be felt and a curve in their penis greater than 30 degrees when treatment is started.
It is not known if XIAFLEX is safe and effective in children under the age of 18.
Who should not receive XIAFLEX?
Do not receive XIAFLEX if you:
Talk to your healthcare provider before receiving this medicine if you have any of these conditions.
What should I tell my healthcare provider before receiving XIAFLEX?
Before receiving XIAFLEX, tell your healthcare provider if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Using XIAFLEX with certain other medicines can cause side effects.
Especially tell your healthcare provider if you take:
Ask your healthcare provider or pharmacist for a list of these medicines, if you are not sure.
Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.
How will I receive XIAFLEX?
Tell your healthcare provider right away if you have trouble stretching or straightening your penis, or if you have pain or other concerns.
How to gently stretch your penis:
Gently stretch your penis 3 times a day. Only stretch your penis if your penis is not hard (erect).
 |
(Figure A)
How to gently straighten your penis:
Gently straighten your penis 1 time a day. Only straighten your penis if you have an erection that happens without any sexual activity (spontaneous erection). Bending your penis should not cause any pain or discomfort.
 |
(Figure B)
What should I avoid while receiving XIAFLEX?
Avoid situations that may cause you to strain your stomach (abdominal) muscles, such as straining during bowel movements.
What are the possible side effects of XIAFLEX?
XIAFLEX can cause serious side effects, including:
See “What is the most important information I should know about XIAFLEX?”
The most common side effects with XIAFLEX for the treatment of Peyronie’s disease include:
Tell your healthcare provider if you have any side effect that bothers you or does not go away.
These are not all of the possible side effects with XIAFLEX. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
General information about the safe and effective use of XIAFLEX.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide.
This Medication Guide summarizes the most important information about XIAFLEX. If you would like more information, talk to your healthcare provider. You can ask your healthcare provider for information about XIAFLEX that is written for health professionals.
For more information, go to www.XIAFLEX.com or call 1-800-462-3636.
What are the ingredients in XIAFLEX?
Active ingredient: collagenase clostridium histolyticum
Inactive ingredients: hydrochloric acid, sucrose, and tromethamine. The diluent contains: calcium chloride dihydrate in 0.9% sodium chloride
This Medication Guide has been approved by the U.S. Food and Drug Administration.
